SULF2 Methylation is Associated with in Vitro Cisplatin Sensitivity and Clinical Efficacy for Gastric Cancer Patients Treated with a Modified FOLFOX Regimen

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 15

PMID 24124496

Citations 6

Authors

Jie Shen

Jia Wei

Hao Wang

Yang Yang

Guofeng Yue

Lin Wang

Lixia Yu

Li Xie

Xia Sun

Xinyu Bian

Zhengyun Zou

Xiaoping Qian

Wenxian Guan

Baorui Liu

Affiliations

Soon will be listed here.

Abstract

Objective: Biomarkers capable of discriminating the patients who are likely to respond to certain chemotherapeutic agents could improve the clinical efficiency. The sulfatases(SULFs) play a critical role in the pathogenesis of a variety of human cancers. Here, we focused our investigation on the prognostic and predictive impact of SULF2 methylation in gastric cancer.

Methods: Promoter CpG island methylation of SULF2 was analyzed in 100 gastric cancer samples. The in vitro sensitivity to cisplatin, docetaxel, gemcitabine, irinotecan and pemetrexed were determined by histoculture drug response assay(HDRA). Additionally, 56 gastric cancer patients treated with a modified FOLFOX regimen(biweekly oxaliplatin plus 5-FU and folinic acid) were retrospectively analyzed to further evaluate the prognostic and predictive impact of SULF2 methylation in gastric cancer.

Results: Methylated SULF2(SULF2M) was detected in 28 patients, while the remaining 72 patients showed unmethylated SULF2(SULF2U, methylation rate: 28%). Samples with SULF2U were more sensitive to cisplatin than those with SULF2M(inhibition rate: 48.80% vs. 38.15%, P = 0.02), while samples with SULF2M were more sensitive to irinotecan than SULF2U(inhibition rate: 53.61% vs. 40.92%, P = 0.01). There were no association between SULF2 methylation and in vitro sensitivity to docetaxel, gemcitabine and pemetrexed. SULF2 methylation was found to have a significant association with cisplatin efficacy(SULF2M: 57.14%, SULF2U: 80.56%, P = 0.02) and irinotecan efficacy(SULF2M: 89.29%, SULF2U: 62.50%, P = 0.01). Among the 56 patients receiving the modified FOLFOX regimen, a significant association was observed between survival and SULF2 methylation status(SULF2M: 309 days, 95% CI = 236 to 382 days; SULF2U: 481 days, 95% CI = 418 to 490 days; P = 0.02). Multivariate analysis revealed that SULF2 methylation was an independent prognostic factor of overall survival in gastric cancer patients treated with platinum-based chemotherapy.

Conclusion: SULF2 methylation is negatively associated with cisplatin sensitivity in vitro. SULF2 methylation may be a novel prognostic biomarker for gastric cancer patients treated with platinum-based chemotherapy.

Citing Articles

SIVA-1 interaction with PCBP1 serves as a predictive biomarker for cisplatin sensitivity in gastric cancer and its inhibitory effect on tumor growth .

Kong F, Shi Z, Huang Y, Chen H, Deng Q, Wu K J Cancer. 2024; 15(13):4301-4312.

PMID: 38947376 PMC: 11212092. DOI: 10.7150/jca.92963.

circRNA_0005529 facilitates growth and metastasis of gastric cancer via regulating miR-527/Sp1 axis.

Zhang X, Yang H, Jia Y, Xu Z, Zhang L, Sun M BMC Mol Cell Biol. 2021; 22(1):6.

PMID: 33472586 PMC: 7816457. DOI: 10.1186/s12860-020-00340-8.

Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.

Wei B, Wang J, Zhang X, Qian Z, Wu J, Sun Y Oncol Lett. 2017; 14(6):6915-6922.

PMID: 29163710 PMC: 5688793. DOI: 10.3892/ol.2017.7069.

Epigenetics in ovarian cancer.

Natanzon Y, Goode E, Cunningham J Semin Cancer Biol. 2017; 51:160-169.

PMID: 28782606 PMC: 5976557. DOI: 10.1016/j.semcancer.2017.08.003.

Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers.

Hull E, Montgomery M, Leyva K Int J Mol Sci. 2017; 18(7).

PMID: 28672878 PMC: 5535854. DOI: 10.3390/ijms18071361.

References

Ai X, Kitazawa T, Do A, Kusche-Gullberg M, Labosky P, Emerson Jr C . SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development. 2007; 134(18):3327-38. DOI: 10.1242/dev.007674. View

Furukawa T, Kubota T, Hoffman R . Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995; 1(3):305-11. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L . ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008; 8:97. PMC: 2394535. DOI: 10.1186/1471-2407-8-97. View

Mutze K, Langer R, Schumacher F, Becker K, Ott K, Novotny A . DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur J Cancer. 2011; 47(12):1817-25. DOI: 10.1016/j.ejca.2011.02.024. View

Hanauske A, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H . In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs. 2007; 25(5):417-23. DOI: 10.1007/s10637-007-9060-9. View

Kim H, Chen J, Yu X . Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science. 2007; 316(5828):1202-5. DOI: 10.1126/science.1139621. View

Chen Z, Fan J, Li J, Li Q, Yan Z, Jia X . Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. Int J Cancer. 2008; 124(3):739-44. DOI: 10.1002/ijc.23960. View

Kudo K, Gavin E, Das S, Amable L, Shevde L, Reed E . Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene. 2012; 31(44):4718-24. DOI: 10.1038/onc.2011.610. View

10.

Shim H, Yun J, Hwang J, Bae W, Cho S, Lee J . BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 2010; 101(5):1247-54. PMC: 11158840. DOI: 10.1111/j.1349-7006.2010.01514.x. View

11.

Hur K, Han T, Jung E, Yu J, Lee H, Kim W . Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer. J Pathol. 2012; 228(1):88-98. DOI: 10.1002/path.4055. View

12.

Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T . Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med. 2009; 48(4):203-8. DOI: 10.2169/internalmedicine.48.1659. View

13.

Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez J . mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 2011; 103(20):1552-6. DOI: 10.1093/jnci/djr326. View

14.

Chen C, Chang Y, Shih J, Lin J, Chen K, Yang C . Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011; 74(1):132-8. DOI: 10.1016/j.lungcan.2011.01.024. View

15.

Tessema M, Yingling C, Thomas C, Klinge D, Bernauer A, Liu Y . SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene. 2011; 31(37):4107-16. PMC: 3307938. DOI: 10.1038/onc.2011.577. View

16.

Dhoot G, Gustafsson M, Ai X, Sun W, Standiford D, EMERSON Jr C . Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science. 2001; 293(5535):1663-6. DOI: 10.1126/science.293.5535.1663. View

17.

Lai J, Chien J, Moser D, Staub J, Aderca I, Montoya D . hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology. 2003; 126(1):231-48. DOI: 10.1053/j.gastro.2003.09.043. View

18.

Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9. DOI: 10.1200/JCO.2005.05.0245. View

19.

Wesolowski R, Lee C, Kim R . Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009; 10(9):903-12. DOI: 10.1016/S1470-2045(09)70136-6. View

20.

Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A, Tanigawa N . Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep. 2009; 21(2):499-505. View